What laboratory tests should be ordered to evaluate pathology in a 65-year-old postmenopausal woman with postmenopausal bleeding who is taking oral estradiol and progesterone and has a family history of endometrial cancer?

Blood Work for Postmenopausal Bleeding Evaluation

In this clinical scenario, blood work plays a limited role—the priority is direct endometrial tissue assessment via endometrial biopsy or imaging with transvaginal ultrasound, not laboratory testing. 1

Primary Diagnostic Approach

The ACR Appropriateness Criteria explicitly state that "the workup of a woman with abnormal bleeding begins with a thorough history, physical examination, and appropriate laboratory tests" but emphasize that imaging (transvaginal ultrasound) and endometrial sampling are the primary diagnostic modalities for postmenopausal bleeding, not blood work 1. The ESMO guidelines similarly note that 80% of endometrial cancers present with postmenopausal bleeding and are diagnosed through direct tissue evaluation 2.

Recommended Laboratory Tests

Essential Basic Labs

• Complete blood count (CBC): To assess for anemia from chronic bleeding and evaluate hemoglobin levels 3

  • Recent research shows hemoglobin levels are significantly lower in malignant cases (p=0.022), and lower hemoglobin is an independent predictor of malignancy (p=0.016) 4
  • Neutrophil and monocyte counts are also elevated in malignant cases and should be noted 4

• Pregnancy test: If any possibility of reproductive potential remains, though unlikely at age 65 3

• Coagulation studies (PT/PTT): Only if bleeding is heavy 3

Inflammatory Markers (Emerging Evidence)

Recent 2026 research suggests peripheral blood inflammatory indices may have adjunctive value 4:

• Neutrophil-to-lymphocyte ratio (NLR)
• Pan-immune-inflammation value (PIV) - identified as an independent predictor of malignancy (p=0.022)
• Systemic immune-inflammation index (SII)
• Systemic inflammation response index (SIRI)

However, these are not standard of care and should not replace tissue diagnosis.

Hormone Testing: Not Recommended

Do not order estrogen, progesterone, or androgen levels. Research shows these hormones "seemed to be indifferent between groups of endometrial cancer and other pathological results" 5. A progesterone challenge test has unacceptable sensitivity (20.8%) and specificity (70.8%) for endometrial pathology screening 6.

Critical Clinical Context

Your patient has multiple high-risk features that mandate tissue diagnosis:

• Age 65 (peak incidence 65-75 years) 2
• Family history of endometrial cancer
• Taking hormone therapy (though combined estrogen-progesterone reduces risk compared to unopposed estrogen) 7

The FDA label for progesterone explicitly states that adding progestin to estrogen "reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone" 7, but this does not eliminate cancer risk entirely.

Definitive Diagnostic Algorithm

1. CBC - assess anemia and inflammatory markers
2. Transvaginal ultrasound - measure endometrial thickness (threshold <4mm has nearly 100% negative predictive value) 1
3. Endometrial biopsy - gold standard for tissue diagnosis 1, 3, 8
4. If endometrium cannot be visualized on ultrasound, proceed directly to biopsy or consider MRI with diffusion-weighted imaging 1

Common Pitfalls to Avoid

• Do not rely on hormone levels to rule out pathology—they lack diagnostic value 5, 6
• Do not delay tissue diagnosis based on normal blood work—endometrial cancer diagnosis requires histopathology 2, 3
• Do not assume hormone therapy is protective—even combined therapy requires evaluation of breakthrough bleeding 7
• Do not skip imaging if biopsy is initially negative—cancers can be missed on first sampling 1